Cite
HARVARD Citation
Rendl, G. et al. (2020). Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria. International journal of endocrinology. p. . [Online].